Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Miriam Alonso-Garcia"'
Autor:
Pablo Remón-Ruiz, Eva Venegas-Moreno, Elena Dios-Fuentes, Juan Manuel Canelo Moreno, Ignacio Fernandez Peña, Miriam Alonso Garcia, Miguel Angel Japón-Rodriguez, Florinda Roldán, Elena Fajardo, Ariel Kaen, Eugenio Cardenas Ruiz-Valdepeñas, David Cano, Alfonso Soto-Moreno
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Nowadays, neither imaging nor pathology evaluation can accurately predict the aggressiveness or treatment resistance of pituitary tumors at diagnosis. However, histological examination can provide useful information that might alert clinicians about
Externí odkaz:
https://doaj.org/article/4b385a986c404fd9bf59481e07ac0815
Autor:
Moreno Eva Venegas, Pablo Remon, Elena Dios-Fuentes, Gutierrez Ana Pinar, Canelo Juan Manuel, Rosario Oliva, Miriam Alonso-Garcia, Eugenio Cardenas, Ariel Kaen, Miguel E. G-Garcia, Gonzales David Cano, Raul M. Luque, Alfonso Soto-Moreno
Publikováno v:
Endocrine Abstracts.
Autor:
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz-Ares, Chao-Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin-Yuan Shih, Kwok Hung Au, Denis Moro-Sibilot, Sotaro Enatsu, Annamaria Zimmermann, Bente Frimodt-Moller, Carla Visseren-Grul, Martin Reck, Quincy Chu, Alexis Cortot, Jean-Louis Pujol, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, James Chung Man Ho, Kwok-Hung Au, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Sang-We Kim, Young Joo Min, Hyun Woo Lee, Jin-Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong-Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan-Vidal, Ernest Nadal-Alforja, Ignacio Gil-Bazo, Santiago Ponce-Aix, Belén Rubio-Viqueira, Miriam Alonso Garcia, Enriqueta Felip Font, Jose Fuentes Pradera, Juan Coves Sarto, Meng-Chih Lin, Wu-Chou Su, Te-Chun Hsia, Gee-Chen Chang, Yu-Feng Wei, Jian Su, Irfan Cicin, Tuncay Goksel, Hakan Harputluoglu, Ozgur Ozyilkan, Ivo Henning, Sanjay Popat, Olivia Hatcher, Kathryn Mileham, Jared Acoba, Edward Garon, Gabriel Jung, Moses Raj, William Martin, Shaker Dakhil
Publikováno v:
The Lancet Oncology. 20:1655-1669
Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inh
Autor:
Markus Wohlleber, Hossein Borghaei, Scott N. Gettinger, Everett E. Vokes, Wilfried Enst Erich Eberhardt, David M. Waterhouse, Enriqueta Felip, Charles Butts, Marco Angelo Burgio, Laura Q.M. Chow, David R. Spigel, Osvaldo Arén Frontera, Miriam Alonso Garcia, Joanna Wojcik-Tomaszewska, Manuel Domine, Scott J. Antonia, Fabrice Barlesi, Rita Chiari, Adam Pluzanski, S. Marimuthu, Grzegorz Czyzewicz, Ang Li, Lucio Crinò, David E. Gerber, Julie R. Brahmer, Neal Ready, Oscar Arrieta, Marina Chiara Garassino, Bruno Coudert, Javier de Castro Carpeño
Publikováno v:
Scientia
J Clin Oncol
J Clin Oncol
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d89b8198e8ce6230aa2c1dd4a7f7a11b
https://hdl.handle.net/11351/7634
https://hdl.handle.net/11351/7634
Autor:
Ang Li, Renata Duchnowska, Konstantin Laktionov, Enriqueta Felip, Dolores Isla, Jacek Jassem, Juergen Wolf, Jan P. van Meerbeeck, Mária Szilasi, W. Appel, Andrea Ardizzoni, Miriam Alonso Garcia, Janusz Milanowski, Enric Carcereny, Richard Griffiths, Luis Paz-Ares, Raffaele Califano, Manuel Cobo, Tudor Ciuleanu, Angelic Acevedo, Sanjay Popat
Publikováno v:
European journal of cancer
Scientia
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Scientia
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Gent gran; Nivolumab; Càncer de pulmó de cèl·lules no petites Anciano; Nivolumab; Cáncer de pulmón de células no pequeñas Elderly; Nivolumab; Non-small cell lung cancer Background CheckMate 171 (NCT02409368) is an open-label, multicentre, pha
Autor:
Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 533 (2022)
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy
Externí odkaz:
https://doaj.org/article/6c4ab7e0320e4541932945c15fccdbcf